Summary
To investigate the regional distribution of valproic acid (VPA) and 10 of its metabolites in the rat brain, the animals were treated with 300 mg/kg/day VPA i.p. on a 3 times daily dose regimen for 5 days, and the concentrations of the compounds in serum and 15 brain regions were measured. 2-(n-propyl)-(Z)-2-pentenoic acid [(Z)-2-en], a VPA metabolite expected to possess neurotoxic potency in humans, was determined in brain tissue for the first time. The brain/serum concentration ratio of (Z)-2-en was found to be about 14-fold higher than the ratio for its (E)-isomer, thereby demonstrating the influence of the double-bond configuration in the unsaturated metabolites on their ability to penetrate into the central nervous system. The concentrations of VPA and its metabolites in the brain regions were compared to chom, the calculated concentration for an assumed homogeneous distribution. The parent drug and its metabolites exhibited individual distribution patterns with varying degrees of inhomogeneity. Elevated metabolite concentrations were found especially in the motorium and the medulla oblongata. Decreased concentrations of VPA and several metabolites were found in the visual cortex.
Similar content being viewed by others
References
Bourgeois B.F.D. (1995): Valproic acid — clinical use. In: Levy R.H., Mattson R.H., Meldrum B.S. (Eds.) Antiepileptic drugs, 4th edn. New York: Raven, 633–639.
Richens A., Davidson D.L.W., Cartlidge N.E.F., Easter D.J. (1994): A multicentre comparative trial of sodium valproate and carbamazepine in adult onset epilepsy. J. Neurol. Neurosurg. Psychiatr., 57: 682–687.
Baillie T.A., Sheffels P.R. (1995): Valproic acid — chemistry and biotransformation. In: Levy R.H., Mattson R.H., Meldrum B.S. (Eds). Antiepileptic drugs; 4th edn. New York: Raven, 589–604.
Löscher W. (1981): Anticonvulsant activity of metabolites of valproic acid. Arch. Int. Pharmacodyn. Ther., 249: 158–163.
Löscher W., Nau H. (1985): Pharmacological evaluation of various metabolites and analogues of valproic acid: anticonvulsant and toxic potencies in mice. Neuropharmacology, 24: 427–435.
Abbott F.S., Acheampong A.A. (1988): Quantitative structure-anticonvulsant activity relationship of valproic acid, related carboxylic acids and tetrazoles. Neuropharmacology, 27: 287–294.
Elmazar M.M.A., Hauck R.-S., Nau H. (1993): Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J. Pharm. Sci., 82: 1255–1258.
Hönack D., Rundfeldt C., Löscher W. (1992): Pharmacokinetics, anticonvulsant efficacy, and adverse effects of trans-2-en-valproate after acute and chronic administration in amygdala-kindled rats. Naunyn-Schmiedebergs Arch. Pharmacol., 345: 187–196.
Palaty J., Abbott F.S. (1995): Structure-activity relationship of unsaturated analogues of valproic acid. J. Med. Chem., 38: 3398–3406.
Schmidt A., Darius J., Brosz M.et al. (1995): The influence of valproic acid monotherapy on behavior and cognitive performance in children with idiopathic generalized epilepsy. Z. Kinder-Jugendpsychiatr., 23: 161–170.
Rohlfs A., Rundtfeldt C., Koch R., Löscher W. (1996): A comparison of the effects of valproate and its major active metabolite E-2-en-valproate on single unit activity of substantia nigra pars reticulata neurons in rats. J. Pharmacol. Exp. Ther., 277: 1305–1314.
Adkison K.D.K., Ojemann G.A., Rapport R.L., Dills R.L., Shen D.D. (1995): Distribution of unsaturated metabolites of valproate in human and rat brain — pharmacological relevance? Epilepsia, 36: 772–782.
Löscher W., Fisher J.E., Nau H., Hönack D. (1989): Valproic acid in amygdala-kindled rats: alterations in anticonvulsant efficacy, adverse effects and drug and metabolite levels in various brain regions during chronic treatment. J. Pharmacol. Exp. Ther., 250: 1067–1078.
Darius J., Meyer F.P. (1996): Concentrations of valproate metabolites under therapeutic conditions. Exp. Toxicol. Pathol., 48: 87–91.
Löscher W., Fisher J.E., Nau H., Hönack D. (1988): Marked increase in anticonvulsant activity but decrease in wet-dog shake behavior during short-term treatment of amygdala-kindled rats with valproic acid. Eur. J. Pharmacol., 150: 221–232.
Popov N., Pohle W., Lössner B.et al. (1973): Regional distribution of RNA and protein radioactivity in the rat brain after intraventricular application of labeled precursors. Acta Biol. Med. Germ., 31: 51–62.
Nau H., Löscher W. (1982): Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and γ-aminobutyric acid (GABA) metabolism in the mouse. J. Pharmacol. Exp. Ther., 220: 654–659.
Löscher W., Nau H. (1983): Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment. J. Pharmacol. Exp. Ther., 226: 845–854.
Yu D., Gordon J.D., Zheng J.et al. (1995): Determination of valproic acid and its metabolites using gas chromatography with mass-selective detection: application to serum and urine samples from sheep. J. Chromatogr. B Biomed. Appl., 666: 269–281.
Darius J. (1996): On-column gas chromatographic-mass spectrometric assay for metabolic profiling of valproate in brain tissue and serum. J. Chromatogr. B Biomed. Appl., 682: 67–72.
Frey H-H., Löscher W. (1978): Distribution of valproate across the interface between blood and cerebrospinal fluid. Neuropharmacology, 17: 637–642.
Adkison K.D., Shen D.D. (1996): Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter. J. Pharmacol. Exp. Ther., 276: 1189–1200.
Hoeppner TJ. (1990): The anticonvulsant valproic acid concentrates in the olfactory bulb: selective laminar localization. Brain Res., 532: 326–328.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Darius, J., Meyer, F.P., Bergsträsser, E. et al. Valproate metabolites in the rat brain — regional distribution in various brain areas. Eur. J. Drug Metab. Pharmacokinet. 24, 97–104 (1999). https://doi.org/10.1007/BF03190017
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF03190017